FDA Approves Unknown Drug — IPCA LABS LTD

# FDA Approves IPCA Laboratories' Generic Drug Application IPCA Laboratories Limited received FDA approval for an abbreviated new drug application (ANDA 209855) on May 29, 2024, expanding the company's generic pharmaceutical portfolio and positioning it to capture market share in a competitive segment. The approval strengthens IPCA's presence in the U.S. generic market and is expected to enhance revenue streams as the company gains access to additional therapeutic categories.